Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

Pfizer ( PFE +0.26%) and Eli Lilly ( LLY +1.80%) are two prominent names in healthcare that have focused on innovation and ...

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...

Novo Nordisk’s next-gen medication is called CagriSema. It’s a once-weekly shot that combines a long-acting amylin analogue ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor ...

The European Medicines Agency's committee on Friday recommended a change to extend the use of Eli Lilly's blockbuster drug Mounjaro for the treatment of type 2 diabetes in adolescents and children ...